Asia Pacific Pharmacovigilance Market Research Report - Segmented By Clinical Trial Phase, By Service Provider, By Method & By Country(India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)
APAC Pharmacovigilance Market Size (2022 to 2027)
As per the research report, the Asia Pacific Pharmacovigilance Market was worth USD 1.07 Billion in 2022 and is estimated to be growing at a CAGR of 14.86%, to reach USD 2.14 billion by 2027.
Pharmacovigilance is the science and activities related to detecting, assessing, understanding, and preventing adverse effects and other drug-related problems. Pharmacovigilance's goals are to provide patient safety by providing a system to collect, assess, and distribute drug safety data. It also involves monitoring approved drugs and investigational medicinal products (IMPs).
The APAC region has the fastest growth rate in the pharmacovigilance market. The number of adverse drug reactions is increasing in the area; thus, there is a rise in pharmacovigilance demand. The biopharmaceutical sector in the region is developing, and there is a lot of research going on in the region on drugs, thus increasing the demand for the pharmacovigilance market. The number of clinical trials in the region is rising, which are working on developing innovative medicines and vaccines, which is solely propelling the market growth. The countries like India, China, Japan, and Australia have the modern infrastructure for pharmacovigilance. The Indian Pharmacopoeia Commission started a training course for the WHO members in the region.
Lack of standardization is a major factor restraining the demand of the market. The number of skilled workforces for pharmacovigilance is less due to fewer training programs, which are slowly hampering the market demand in the Asia Pacific. In addition, the lack of awareness in undeveloped countries is hindering the growth rate of the market. Stringent rules and regulations by the government are also impeding the demand of the market.
This research report on the APAC pharmacovigilance market has been segmented and sub-segmented into the following categories:
By Clinical Trial Phase:
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Phase IV
By Service Provider:
- In-house
- Contract Outsourcing
By Method:
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
By Country:
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC
The Indian pharmacovigilance market is estimated to be growing at a brisk pace. The Indian government launched the PvPI (Pharmacovigilance program of India) with the NCC (National Coordination Centre), which monitors India's adverse drug reaction. The rising geriatric population is also a factor in the growth of the market.
The Chinese pharmacovigilance market has the largest share in the Asia Pacific market. The Chinese pharmacovigilance market is one of the leading markets in the world. The government has launched the CADRMS (China adverse drug reaction monitoring system) to monitor the country's ADRs.
The Australian pharmacovigilance market is predicted to have a promising growth rate in the coming years. Escalating expenditure on healthcare is to lavish the growth rate of the market in the coming years.
KEY MARKET PLAYERS:
Boehringer Ingelheim, Accenture, Bristol-Myers Squibb, Covance, ICON, PAREXEL, Quintiles, United BioSource, Synowlwedge, and Cognizant Technology Solutions Corporation are a few of the prominent companies in the APAC pharmacovigilance market profiled in this report.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Clinical trial phase
5.1.1 Introduction
5.1.2 Pre-clinical
5.1.3 Phase I
5.1.4 Phase II
5.1.5 Phase III
5.1.6 Phase IV
5.1.7 Y-o-Y Growth Analysis, By Clinical trial phase
5.1.8 Market Attractiveness Analysis, By Clinical trial phase
5.1.9 Market Share Analysis, By Clinical trial phase
5.2 Service provider
5.2.1 Introduction
5.2.2 In-house
5.2.3 Contract outsourcing
5.2.4 Y-o-Y Growth Analysis, By Service provider
5.2.5 Market Attractiveness Analysis, By Service provider
5.2.6 Market Share Analysis, By Service provider
5.3 Method
5.3.1 Spontaneous Reporting
5.3.2 Intensified ADR Reporting
5.3.3 Targeted Spontaneous Reporting
5.3.4 Cohort Event Monitoring
5.3.5 EHR Mining
5.3.5 Y-o-Y Growth Analysis, By Method
5.3.6 Market Attractiveness Analysis, By Method
5.3.7 Market Share Analysis, By Method
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Clinical trial phase
6.1.3.3 By Service provider
6.1.3.4 By Method
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Clinical trial phase
6.1.4.3 By Service provider
6.1.4.4 By Method
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Clinical trial phase
6.1.5.3 By Service provider
6.1.5.4 By Method
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Boehringer Ingelheim
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Accenture
8.3 Bristol-Myers Squibb
8.4 Covance
8.5 ICON
8.6 PAREXEL
8.7 Quintiles
8.8 United BioSource
8.9 Synowlwedge
8.10 Cognizant Technology Solutions Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Asia Pacific Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- Asia Pacific Pre-clinical Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Phase I Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Phase II Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Phase III Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Phase IV Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
- Asia Pacific In house Market, By Region, From 2022 - 2027 (USD Million)
- Asia Pacific Contract outsourcing Market, By Region, From 2022 - 2027 (USD Million)
- Japan Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- Japan Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
- China Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- China Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
- India Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- India Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
- Australia Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- Australia Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
- South Korea Pharmacovigilance Market, By Clinical trial phase, From 2022 - 2027 (USD Million)
- South Korea Pharmacovigilance Market, By Service provider, From 2022 - 2027 (USD Million)
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
